Denali Therapeutics Inc.

DNLI Nasdaq CIK: 0001714899

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
Mailing Address 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
Phone (650) 866-8547
Fiscal Year End 1231
EIN 463872213

Financial Overview

FY2025 FY

$330.53M
Revenue
$1.23B
Stockholders' Equity
$205.33M
Cash & Equivalents
$-1.06
EPS

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 31, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment March 26, 2026 View on SEC
8-K Current report of material events March 25, 2026 View on SEC
8-K Current report of material events February 26, 2026 View on SEC
10-K Annual financial report February 26, 2026 View on SEC
4 Insider stock transaction report January 8, 2026 View on SEC
4 Insider stock transaction report January 8, 2026 View on SEC
8-K Current report of material events January 6, 2026 View on SEC
4 Insider stock transaction report January 5, 2026 View on SEC
4 Insider stock transaction report January 5, 2026 View on SEC

Insider Trading

SELL 2 insiders 2 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.